EvaluatePharma - Merz - Worldwide

Merz	All Financial Data in US $ (mln)Show in reporting currency

Worldwide

Overview

Company News

Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KGaA Settle NAMENDA(R) Patent Litigation
Forest Laboratories (July 22, 2010)

Mylan Announces Settlement Agreement for Namenda®
Mylan (July 22, 2010)

Novabel(1) : Letter to Customers : Suspension of Shipments
Biocompatibles International (June 30, 2010)

Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type
Forest Laboratories (June 21, 2010)

Sun Pharma Announces USFDA Approval for Generic Namenda® Tablets
Sun Pharmaceutical Industries (May 06, 2010)

Sun Pharma Announces USFDA Tentative Approval for Generic Namenda® Tablets
Sun Pharmaceutical Industries (April 10, 2010)

Merz to Complete Acquisition of BioForm Medical
Merz (February 19, 2010)

Merz Pharma Group Successfully Completes BioForm Medical Tender Offer With Over 94 Percent of Shares Tendered
Merz (February 16, 2010)

Announcement of Approval Application in Japan for Manufacturing and Marketing of SUN Y7017 (Memantine) for the Treatment of Alzheimer's Type Dementia
Daiichi Sankyo (February 08, 2010)

Merz and Acumen Partner in Innovative Alzheimer’s Approach
Merz (January 12, 2010)

Displaying 10 out of a possible 164 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Merz, a privately held healthcare company based in Germany. Merz Pharma contributes approx. 80% to total group sales (balance of sales from Merz & Krell, a writing instrument manufacturer). Source of information: company website provides details of annual turnover for group and pharmaceutical sales; Merz published an annual report for the first time for fiscal 2005 (JUL 2004 - JUN 2005).
Listed or Private Company	Private
Company Classification	Regional Major
Company Website	Website

Full Company Profile Information

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Axura	memantine hydrochloride	Nootropics	146²	167³	+14%

Note: Shaded Cells⁴

RX Sales Chart

Merz	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals	804	809	+1%

Therapy Area Focus in 2008

Merz
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Central Nervous System	167
Other Rx & OTC Pharma	642

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Merz ⁵	28

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXXX XXXXXXX:
XXXX XXXXX XXXXX XX XXXXXXX.

XXXXXXXX XXXXX XXXXX XX XXXXXX XXXX XXXXXXXXX XXXXXXX XX XXXX.

XXXXXX XXXX XXXXX XXXXXXX XX XX XXXX XXXXXXXXX XXXXXXX XX XXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXXX XXXXXXX (XX XXX XXXX):

XXXXXXXXX'X XXXXXXXXXX XXXXXXXXX XXXXXXX XXXXXXXXXXX XXXX XX X XXXXXXX XX XXXXXXX

XXX XXXXXXXXX XXXXXXXXXX XXXXXXXXX XXXXXX XXXXXXXXXX XXXXXXXXX XXX XXXXXXXX XX XXXX XXXXXXXXXXXXXXX, XXXXXXXXX, XXXXXXX, XXX XXX XXXXXXXXX XX XXXXXXXX XX XXXXXX XXXXXXXXX'X XXXXXXX XXX XXXXXXXXX XXX X XXXXXXX XX XXXXXX XXXX. XXX XXXXXXX XX XXXXXXXX XXXXX XXX XXXXX XXXXX XXXXXXX®, XXXXX®, XXXXX® XXX XXXXXXXX® XXX XXXXX XXXXXX XXXXX XXXXXXXXX XX XXX XXXXXX XX XXXXXXXXXXXXX XXXXXXX XXX XX.

XXXXXXXXX XXXX XXXXXXXXX XX XXXXXXXXXXXX XX XXXXXX XXX XXXXX XXXX XX XXXX XXXXXXXXX'X XXXXXXXX XXX XXXXX XXXXX XXXX XXXX XXXXXXX. XXX XXXXXX XXXXXX XXXXXXXXX XXXXXXXX XXXXX XXXXX XXXX XXX XXXXXXXX XXXXXXX XX XXX XXXXXXXXXXXXXX XX XXXXXXXXX XXXXX XX XXX XXXXX XXXXXX XX XXXXXXXXX'X XXXXXXXX. XXX XXXXXXXXXX XX XXXX XXXXXXXXXXXXXX XXXXXXX XXX XXX XX XXXXXXXXX XXX XXXXXXXXXXXXX XXXX XXX XXXXXXXX XX XXXXXXXX XXX XXXXXXX XXX XXXXXXXX.

XX. XXXXXX XüXXXXXX, XXXXXXXX XX XXX XXXXXXXXXXXX' XXXXXXX XX XXX XXXX XXXXX XXXX, "XXXXXXX XXX XXXXXXX XXXX XX XXXX XXXXXXX XX XXX XXXXX XXXX XXX XXXX XXXXX XXXXX XX XXXXXXXX XXXXXXX XX XXX XXXXXXX XXX XX XXXXXXXXX, XXX XXXXXXX XXX XXXXXXXXX XXXX XX XXX XXXXXXXX XXXXXX XXXXXXXXXXXX XXX XXXXXXXX XXX XXXXXX XXXXXXXXX XX XXXXXX XXX XXX XX, XX XXXXX XXXXX XXXX XXX XXXX XXXX XX XXXXXXX."

XXXXXXXXX XXXXX XXXX XXXXX XXXXXXXXXXXX XXXXX XXX XXXXXX XX XXX XXXXXX, XXXXXXXX XXX XX XXXXXXX. XX. XXXXXX XüXXX, XXX XX XXXX XXXXXXXXXXXXXXX XXXX, "XX XXX'X XXXX XX XXXX XX XXX XXXXXXX XXXXX XXXXXXXX XXXX XXXX. XXX XXXX XXX XXX XXXXXX XXXX XXXXXXXX XX XX XX XXXXXXX XXXXXXXXX XX XXX XXXXXXX XXXXXXX XX XXXXX XX XXXXXX XXXX XX XXXX XXXXXXXX XX XXXXXXXX XXXX XXXXXXX XXXXXXXXX XXXXXXXXX. XX XXXX XXXX XXXXXXXX XX XXXX XX XXX XXXXXXXX XX XXX XXXXXXXXXX XX XXXXXXXXX'X XXXXXXXX."

XXXXXXXX XXXXXXX:
XXXX XXXXX XXXXX XX XXXXXXX.

XXXXXXXX XXXXX XXXXX XX XXXXXX XXXX XXXXXXXXX XXXXXXX XX XXXX.

XXXXXX XXXX XXXXX XXXXXXX XX XX XXXX XXXXXXXXX XXXXXXX XX XXXX.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XXX XXXX-XXX XXXX) (XX XXX XXXX):
XX XXX XXXXXX XXXXXX XXX XXXXXXXX XXXXXXXXXX, XXXXX XXXXXX XX XXXXXXXXX (XXXXX®) XXX XXXXXXXXXXXX XXXXXXX, XXXXXXXXXX XX XX%. XX XXXXXXXXXX, XXX XXXXXXXXXX XXXXXX XX XXXXX® XXXX XXXX-XXXXXX XXXXXXX XXX X XXXX-X-XXX XXXXXX XXX XXX XXX XXXXX® XXXXXXX XXXX XXXX XXXXXXXXXXX XX XXXX XXXXX XXXXX XXXX XXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXXXX: XXXXXX XXXXXXXXXXXX XXXXXX XXXX XX-X (XX XXX XXXX), XXXX XX:
XXXXXXX XX XXXXXXX XX X X.X. XXXXXX XX XXX XXXXXX XXXXX XXXXXXX XX XXXX. XX XXXXX XXXX XXX X.X. XXXXXX XXX XXXXXXXXX XXXXXX XXXXXX X XXXXXX XX XXXXX XXXXXXXXXXXXX XXXX XXXXXXX XX XXXXXXXX XX X XXXXXX XXXX XXXXXXXXX XXXXX XXXXX XXXX. XX XXXXXXX XXXX, XX XXX XXXX XXXXXXXXX XXXXXX XXXXXXXXXXXX XXXXXXXXXX XXXXXXX XXXXXXX XXXXXXX XXXXXXXXXXXXX XXX XXX XXXXX XXXXX XXXXXXX XXX XXXXXXXX XX XXXXXX XXXXXXX XXXXXXXXXXX XX XXXXXXX. XXX XXXXXXX XXX XXXXXXX XX XXX XXXXXX XXXXXX XXXXXXXX XXXXX XXX XXX XXXXXXXX XX XXXXXXXX. XX XXXXXX XX XXXXX XXXXXXX XXX XXXXXX XXXXXX XXX XXXXXXX.

XX XXXXXXXX XXXX, XX XXXXXXXX XXXXXXXXXXX XXXXXXX XX X XXXXX XXX XXXXX XX XXXXXXXXX XXX XX X XXXXX XXXX-XXXXX XXXXXXXXXXX. XXX XXXXX XXXXXXXXX XXX XXXXXXXX, XXXXXX XXX XXXXXXXXXXXX XX XX XXXXXXXXXX, XXXXXXXXXXX, XX XX XXXXXXXXX XXXXXXXX-XXXXXXX, XXXX-XXXXX XXXXXXXXXXX XXXXXXXX XX XXXXXXX XX XXXXXXXXXXX XXXX XXXXXXXX XXX XXXXXX XXXXXXXXX’X XXXXXXX XXXXXXXXX XXXXXXX XXXX XX XXXXXX- XXXXXXXXXXXXXX XXXXXXXXX. XXX XXXXXXX XXXXXXXXX XXXX XXXXXXXX XXXXXXX XXXX XXXXXXXXX XX XX XXXXXXXX-XXXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXXXX XXXXXXXX XX XXXXXXXXX XXX XXXXXXXX XXXXXX XXXXXX XXXXXXXX XX XXXXXXX. XXXXX XX XXX XXXXXXX XX XXXX XXXXX, XX XXXXXX XX XXXXXXX X XXX XXX XXXX XXX XXXXXXXXXXX.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.